RAPID CASE ASCERTAINMENT SHARED RESOURCE (RCA) PROJECT SUMMARY/ABSTRACT The Rapid Case Ascertainment program (RCA) was originally developed in 1986-1987 in response to a Connecticut Hospital Association (CHA) request to establish a single entity that would be responsible for all population-based cancer epidemiology studies that directly involve Connecticut hospitals. RCA assists cancer researchers in implementing and executing their studies by providing high-quality and cost-effective study management, cancer case identification, patient enrollment and interview, medical record abstraction, and pathology specimen collection services so that investigators can accomplish their scientific goals. During our most recent funding period (FY17), 19 people have used RCA. Thirteen of these users (68%) were YCC members. The majority of this use came from Cancer Prevention and Control (CPC) Research Program. The Rapid Case Ascertainment Shared Resource (RCA) facilitates cancer research and population-based studies of cancer for YCC investigators, as well as outside investigators, who wish to conduct research in the state of Connecticut (YCC catchment area). RCA addresses the many administrative tasks common to all proposed hospital-based research in the state and provides a uniformly high-quality, well-coordinated interface with those individuals, institutions, and agencies crucial to the success of cancer research. RCA also supports rapid cancer case identification for research and clinical purposes. RCA functions as an agent of the Connecticut Tumor Registry, as designated by the Commissioner of Public Health. RCA is led by Rajni Mehta who has a master?s degree in Public Health.
The Specific Aims of the RCA Shared Resource are to: (1) Provide consultation and assistance to investigators in protocol writing in appropriate areas (protection of human subjects, HIPAA regulations, confidentiality, etc.); (2) Obtain approvals to conduct the research and submit annual reports and requests for re-approvals to all non-Yale IRBs; (3) Identify patients with incident cancers; (4) Serve as an honest broker in studies that require the investigators to not know the identity or the individuals whose data or specimens are being used for research (de-identified research); (5) Perform data collection and pathology specimen collection; (6) Facilitate research across the state of CT (YCC catchment area), as well as targeting areas of higher cancer risk (e.g., cities of Hartford, New Haven. and Bridgeport).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-41
Application #
9989591
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
41
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331

Showing the most recent 10 out of 675 publications